news
First patient enrolled in cisplatin-induced ototoxicity Phase II trial
A Phase II proof of concept trial evaluating SENS-401 for cisplatin-induced ototoxicity has enrolled its first patient.
List view / Grid view
Sensorion
article
Learning the unwritten rules and dynamics of power
As part of EPR’s Women in Pharma series, Nawal Ouzren, CEO of Sensorion, talks to Science Editor Dr Zara Kassam about the diversity in drug development, creating a new growth mindset and elevating conversations beyond obvious beliefs...
